PUBLIC COMPANY
save$MBXMBX Biosciences, Inc.
$MBX66.15-2.46%Carmel, IN, USupdated 15h ago
community read0 votes
pipeline
3
marketed
0
phase 3
0
catalysts ytd
1
approvals ytd
0
recalls ytd
0
Pipeline(3)
pipeline depth3 products
1Phase 12Phase 2
Upcoming
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase1A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MBX 4291 in Adult Participants With Obesity
- phase2Safety, Pharmacokinetics and Efficacy of MBX 2109 in Patients With Hypoparathyroidism
- phase2Study to Evaluate Efficacy and Dose Response of Imapextide (STEADI)
- phase2Extension Study to Evaluate the Long-Term Safety and Tolerability of MBX 2109 in Patients With Hypoparathyroidism
- phase1Safety and Pharmacokinetics Study of MBX 2109 in Adult Subjects With Normal and Impaired Renal Function
- phase1Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of MBX 1416 in Healthy Subjects
- phase1Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of MBX 2109 in Healthy Adult Subjects
Insider activity
source: SEC Form 4open-market buys + sells
- Mar 13, 26BUYHawryluk P. Kent· President & CEO$526K↗
routine RSU / option mechanics (2)
- Feb 26, 26option exerciseHawryluk P. Kent · President & CEO28,768 sh
- Feb 26, 26option exerciseHawryluk P. Kent · President & CEO28,768 sh
🐶 Hiring Signal
next earnings Nov 5, 2026
News
no news has mentioned this company yet
Data sources
last refreshed 24m ago
Found something off?
comments(0)
5-min edit window · permanent after that